Page 28 - Loss Attributable News Today

Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update

- Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones - - SerpinPC registration studies planned to begin in 2H 2022 following

30.03.2022 - – Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones – – SerpinPC registration studies planned to begin in 2H 2022 following recent FDA meeting; initial focus on ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

24.03.2022 - RESTON, Va., March 24, 2022 (GLOBE NEWSWIRE) - Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, announced its financial results for the year ended December 31, 2021, and provided an update on the Companys ...

/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...

/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...

Oil-Dri Corporation of America , producer and marketer of sorbent mineral products, today announced results for its second quarter and first six-months of fiscal year 2022. ... | March 11, 2022

Established Exclusive Worldwide Collaboration and License Agreement with Roche and Genentech for the Development and Commercialization of RG6501 (OpRegen®) in Transaction Worth up to $670 MillionRetinal Tissue Restoration and Visual Improvements Reported in Four Patients Treated with RG6501 (OpRegen) for Dry Age-Rel...

/PRNewswire/ -- Inpixon® (Nasdaq: INPX), the Indoor Intelligence® company, today provided a business update and reported financial results for the fiscal year...